An efficacy of ninedanib in patients with idiopathic pulmonary fibrosis (two case reports)
https://doi.org/10.18093/0869-0189-2019-29-4-486-492
Abstract
Idiopathic pulmonary fibrosis (IPF) is an irreversible progressive diffuse parenchymal lung disease with the median survival of 3 to 5 years. However, antifibrotic therapy can significantly reduce IPF progression rate. The natural course of the disease is difficult to predict in an individual patient. The prognosis and the response to therapy could differ in different IPF patients. Two clinical cases with modified rate of IPF progression under the treatment with nintedanib are described in the article. The late initiation of therapy with nintedanib in a patient with rapidly progressive disease did not slow down the progression rate, while a patient with a relatively favorable course of IPF demonstrated less rapid worsening in clinical and functional parameters under the treatment with nintedanib.
Conclusion. The time-course of clinical and functional parameters is individually related to the disease severity and the potential therapeutic efficacy. The rapidly progressive course of IPF should be considered as a criterion for early initiation of antifibrotic therapy as this treatment could improve the prognosis. Effects of antifibrotic therapy should be assessed using a complex of parameters described the disease severity because IPF can differ in clinical course and progression rate.
About the Authors
S. A. Terpigorev
M.F.Vladimirskiy State Moscow Regional Research Clinical Institute
Russian Federation
Russian Federation
Stanislav A. Terpigorev, Doctor of Medicine, Head of Department of Occupational Diseases and Medical Expertise
ul. Shchepkina 61/2, Moscow, 129110
A. M. Nikishenkov
M.F.Vladimirskiy State Moscow Regional Research Clinical Institute
Russian Federation
Russian Federation
Aleksey M. Nikishenkov, Researcher, Department of Occupational Diseases and Medical Expertise
ul. Shchepkina 61/2, Moscow, 129110
S. G. Nikishenkova
M.F.Vladimirskiy State Moscow Regional Research Clinical Institute
Russian Federation
Russian Federation
Svetlana G. Nikishenkova, Resident Physician, Department of Occupational Diseases and Medical Expertise
ul. Shchepkina 61/2, Moscow, 129110
References
1. Raghu G., Collard H.R., Egan J.J. et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 2011; 183 (6): 788–824. DOI: 10.1164/rccm.2009-040GL.
2. Chuchalin A.G., Avdeev S.N., Aisanov Z.R. et al. Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis. Federal Guidelines. Pul'monologiya. 2016; 26 (4): 399–419. DOI: 10.18093/0869-0189-2016-26-4-399-419 (in Russian).
3. Travis W.D., Costabel U., Hansell D.M. et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am. J. Respir. Crit. Care Med. 2013; 188 (6): 733–748. DOI: 10.1164/rccm.201308-1483ST.
4. Raghu G., Chen S.Y., Yeh W.S. et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001–11. Lancet Respir. Med. 2014; 2 (7): 566–572. DOI: 10.1016/S2213-2600(14)70101-8.
5. Raghu G., Remy-Jardin M., Myers J.L. et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am. J. Respir. Crit. Care Med. 2018; 198 (5): e44–e68. DOI: 10.1164/rccm.201807-1255ST.
6. Collard H.R., Ryerson C.J., Corte T.J. et al. Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report. Am. J. Respir. Crit. Care Med. 2016; 194 (3): 265–275. DOI: 10.1164/rccm.201604-0801CI.
7. Kondoh Y., Cottin V., Brown K.K. Recent lessons learned in the management of acute exacerbation of idiopathic pulmonary fibrosis. Eur. Respir. Rev. 2017; 26 (145): pii: 170050. DOI: 10.1183/16000617.0050-2017.
8. Lancaster L., Crestani B., Hernandez P. et al. Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials. BMJ Open Respir. Res. 2019; 6 (1): e000397. DOI: 10.1136/ bmjresp-2018-000397.
9. Richeldi L., du Bois R.M., Raghu G. et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014; 370 (22): 2071–2082. DOI: 10.1056/NEJMoa1402584.
10. Kreuter M., Swigris J., Pittrow D. et al. The clinical course of idiopathic pulmonary fibrosis and its association to quality of life over time: longitudinal data from the INSIGHTS-IPF registry. Respir. Res. 2019; 20 (1): 59. DOI: 10.1186/s12931-019-1020-3.
11. Crestani B., Huggins J.T., Kaye M. et al. Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON. Lancet Respir. Med. 2019; 7 (1): 60–68. DOI: 10.1016/S2213-2600(18)30339-4.
12. Fabrellas F.E., Sanchez P.R., Abad S.C., Juan J.G. Prognosis and follow-up of idiopathic pulmonary fibrosis. Med. Sci. (Basel). 2018; 6 (2): pii: 51. DOI: 10.3390/medsci6020051.
Review
For citations:
Terpigorev S.A., Nikishenkov A.M., Nikishenkova S.G. An efficacy of ninedanib in patients with idiopathic pulmonary fibrosis (two case reports). PULMONOLOGIYA. 2019;29(4):486-492. (In Russ.) https://doi.org/10.18093/0869-0189-2019-29-4-486-492
Views:
850
Email this article 